Ratings Enovis Corporation

Equities

ENOV

US1940145022

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
55.26 ^USD	+0.29%		-1.02%	-1.36%

Apr. 09	Transcript : Enovis Corporation Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-09-2024 03:45 PM
Feb. 23	Canaccord Genuity Ups Price Target on Enovis to $75 From $73, Maintains Buy Rating	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The company's share price in relation to its net book value makes it look relatively cheap.
Over the last twelve months, the sales forecast has been frequently revised upwards.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The company has insufficient levels of profitability.
The company is in debt and has limited leeway for investment
With an expected P/E ratio at 50.7 and 35.11 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The valuation of the company is particularly high given the cash flows generated by its activity.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
ENOVIS CORPORATION	-1.36%	3.03B		B-
STRYKER CORPORATION	+12.07%	128B		A-
SMITH & NEPHEW PLC	-9.04%	10.65B		A-
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+0.91%	8.82B		C
INSPIRE MEDICAL SYSTEMS, INC.	+16.72%	7.19B		C
GLAUKOS CORPORATION	+25.15%	4.99B		B+
AXONICS, INC.	+7.17%	3.4B		C-
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-8.73%	2.14B	-	-
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-10.15%	2B		-
DOUBLE MEDICAL TECHNOLOGY INC.	-22.81%	1.79B	-	C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes